Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19

Download in PDF

Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.

Key words

COVID-19, hyperinflammatory syndrome, cytokine storm, IL-6 inhibitors, olokizumab.